Alan Naylor

Apax Partners LLP engages in providing investment services. It focuses on investing in firms across the global sectors such as technology and telecommunications, services, healthcare, and consumer. The company was founded by Ronald Mourad Cohen and Alan J. Patricof in 1969 and is headquartered in London, the United Kingdom.

Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom.

Cancer Therapeutics CRC Pty Ltd. engages in research and development novel oncology drug and clinical diseases. It focuses in recombinant protein production, structural biology, DMPK, and translational cancer biology. The company was founded in 2007 and is headquartered in Melbourne, Australia.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

Medical Research Commercialisation Fund Trust invests in life science companies located in Australia. The fund focuses on companies operating in the fields of medical research institutes and allied research hospitals. It provides seed and early stage financing in project investment of up to $0.02 million, at the stage of company formation invests up to $4 million and also makes follow-on investments of up to $2 million. It seeks co-investment with other investors for technologies with larger capital requirements.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

MiReven Pty Ltd. operates as an Australian biopharmaceutical company. The private company is based in Nedlands, Australia.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

MecRx Pty Ltd. develops drugs for treatment of cancer. The company was founded by Ian Holmes, Jo Alcindor, Tom Peat and Janet Newman in 2013 and is headquartered in Melbourne, Australia.

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia.

MetabloQ Pty Ltd. develops drugs for cancer treatment. It treats triple-negative breast cancer, prostate cancer and melanoma cancer diseases. The company was founded in 2016 and is headquartered in Melbourne, Australia.

Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia.

Baker Heart & Diabetes Institute owns and operates a medical research institute. The company is headquartered in Melbourne, Australia.

Certa Therapeutics Pty Ltd. operates as biotechnology company. The firm develops drugs for treatment for kidney disease. The company was founded by Darren James Kelly and is headquartered in Melbourne, Australia.

Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom.

Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia.

Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

Respirion Pharmaceuticals Pty Ltd. operates as a biotechnology firm. It focuses on development new treatments for respiratory diseases. The company was founded by Barry Clements in 2018 and is headquartered in Iluka, Australia.

Australian Investment Council is an Australian private company located in Sydney. The firm operates as an association. Navleen Prasad has been the CEO since 2022.

Ankere Therapeutics develops therapeutics for inflammatory diseases. The Australian company was founded by Stuart Pitson, Bernard Flynn. Bernard Flynn has been the CEO since incorporation.